Deutsche Bank downgraded Sanofi to Sell from Hold with an unchanged price target of EUR 90. Sanofi posted a "mixed" start to FY23, further confirming both a limited chance of management overdelivering on the numbers this year as well as the realization that the 32% margin target for FY25 "is not being lowballed," the analyst tells investors in a research note. In the mid-term, a fundamental problem for Sanofi is struggling productivity, the firm adds.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on SNY:
- Sanofi completes acquisition of Provention Bio
- Sanofi confirms FY23 business EPS view of up low single digits at CER
- Sanofi reports Q1 business EPS EUR 2.16, up 11.9% at CER
- Hart-Scott-Rodino waiting period expires for Sanofi’s acquisition of Provention
- ALX Oncology enters clinical trial collaboration with Sanofi
